Intra‑Aortic Balloon Pump (IABP) – Indications, Hemodynamics, and Management

Indications for IABP Support

IABP should be used as first‑line mechanical support in patients who fail to wean from cardiopulmonary bypass after cardiac surgery, because postoperative experience shows favorable outcomes. Level B evidence. [1][2]
IABP is indicated when escalating doses of inotropic agents (e.g., dobutamine or milrinone) do not achieve adequate cardiac output augmentation in acute decompensated heart failure. Level B evidence. [1][2]

Routine use of IABP in acute myocardial‑infarction‑related cardiogenic shock is not recommended; the IABP‑SHOCK II randomized trial demonstrated no reduction in 30‑day or 12‑month mortality. Level A evidence (RCT). [1][2]
Severe peripheral‑vascular disease is a contraindication because of a high risk of vascular injury and limb ischemia. Level B evidence. 1

IABP provides a modest increase in cardiac output of approximately 0.5 L/min on average. Level B evidence. [1][2]
Stroke volume is increased during balloon deflation, contributing to the modest cardiac‑output rise. Level B evidence. [1][2]
Systolic arterial pressure is augmented during balloon inflation, helping maintain systemic perfusion. Level B evidence. [1][2]
The device unloads the left ventricle and reduces pulmonary‑arterial pressures, aiding end‑organ decongestion. Level B evidence. [1][2]

The percutaneous femoral artery approach is the most common insertion site, but it severely limits patient mobility and is associated with short‑term use only. Level B evidence. [1][2]
Support duration via femoral access should be limited because of arterial complications and immobilization; typical use is short‑term (≤ 3 days). Level C evidence. 3
A subclavian/axillary artery approach (graft‑anastomosed to the right subclavian) permits patient mobilization and longer support periods when needed. Level B evidence. [1][2]

1–3 days of IABP support is usually sufficient to achieve hemodynamic optimization (decongestion of lungs, liver, kidneys; reduction of pulmonary pressures; improvement of end‑organ function). Level B evidence. 1
If target hemodynamic improvement is not observed within this window, clinicians should avoid delaying durable mechanical circulatory support and consider escalation to surgically placed temporary devices or definitive long‑term support. Level B evidence. 1

The most common major complications are vascular injury, bleeding, and infection; these risks increase with prolonged femoral support. Level B evidence. 1
To mitigate risk, limit the duration of IABP support and consider alternative access (subclavian/axillary) for patients who require longer support. Level B evidence. [1][2]

In acute myocardial infarction, IABP was associated with lower in‑hospital mortality after lytic therapy, but no mortality or multiorgan‑dysfunction benefit after percutaneous coronary intervention. Level B evidence. [1][2]
Contemporary percutaneous circulatory‑support devices (e.g., Impella, TandemHeart) generate greater increases in cardiac index and mean arterial pressure (≈ 2.5–5.0 L/min) compared with IABP, yet 30‑day mortality outcomes are similar. Level B evidence. [1][4]
Optimal patient selection is critical: the greatest benefit of IABP is seen in postcardiotomy cardiac dysfunction and selected acute decompensated heart‑failure phenotypes, rather than routine use for all forms of cardiogenic shock. Level B evidence. [1][2]